---
title: "默克：在相关研究中，KEYTRUDA 联合 PADCEV 使用 使膀胱癌患者的死亡风险降低 50%，使复发和扩散事件的风险降低了 60%。"
description: "默克：在相关研究中，KEYTRUDA 联合 PADCEV 使用 使膀胱癌患者的死亡风险降低 50%，使复发和扩散事件的风险降低了 60%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261731590.md"
published_at: "2025-10-18T14:38:10.000Z"
---

# 默克：在相关研究中，KEYTRUDA 联合 PADCEV 使用 使膀胱癌患者的死亡风险降低 50%，使复发和扩散事件的风险降低了 60%。

默克：在相关研究中，KEYTRUDA 联合 PADCEV 使用 使膀胱癌患者的死亡风险降低 50%，使复发和扩散事件的风险降低了 60%。

### Related Stocks

- [MRK.US - 默克](https://longbridge.com/zh-CN/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing | 04:30 PM EST, 02/06/2026 (MT Newswires) -- Johannes Jacobus Oosthuizen, President, US Market, on February 06, 2026, sold | [Link](https://longbridge.com/zh-CN/news/275175518.md) |
| Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | [Link](https://longbridge.com/zh-CN/news/274841608.md) |
| MSD receives FDA approval for Keytruda combo to treat ovarian cancer | MSD has received FDA approval for Keytruda and Keytruda Qlex, in combination with paclitaxel, for treating platinum-resi | [Link](https://longbridge.com/zh-CN/news/275742611.md) |
| FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer | The FDA has approved Merck's KEYTRUDA regimen for treating adults with PD-L1 positive platinum-resistant ovarian cancer. | [Link](https://longbridge.com/zh-CN/news/275598070.md) |
| Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX | Merck announced that the U.S. FDA has approved KEYTRUDA (pembrolizumab and berahyaluronidase alfa-pmph) for treating adu | [Link](https://longbridge.com/zh-CN/news/275617117.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。